Women's health

Biotech

ObsEva sells off one of 2 remaining assets to stay afloat

Only two months after cutting staff by 70% to focus much of its remaining resources on preterm labor treatment ebopiprant, ObsEva is now selling it.
James Waldron Nov 22, 2022 7:35am

FDA, Edwards on how devicemakers can better serve women

Oct 26, 2022 2:12pm

Astellas' menopause therapy accepted for FDA review

Aug 18, 2022 8:50am

Hologic caps off year of European expansion with new French HQ

Mar 24, 2022 1:05pm

Astellas gets safety win for menopause in late-stage trial

Mar 7, 2022 10:12am

With approval in sight, ObsEva offloads women's health drug 

Feb 11, 2022 4:54am